{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"18"}]}],"title":"Adverse Events (AEs)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"11"}]}],"title":"Serious Adverse Events (SAEs)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Number of participants with any grade of adverse events (AEs) and any grade of serious adverse events (SAEs) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v4.0)","groups":[{"description":"Asymptomatic patients treated with Nivolumab IV 1 mg/kg Q3W + Ipilimumab IV 3 mg/kg Q3W for a total of 4 doses of the combination therapy followed by Nivolumab IV 3 mg/kg BID for a maximum of 24 months or until progression or until unacceptable toxicity.","id":"OG000","title":"Cohort A"},{"description":"Symptomatic patients treated with Nivolumab IV 1 mg/kg Q3W + Ipilimumab IV 3 mg/kg Q3W for a total of 4 doses of the combination therapy followed by Nivolumab IV 3 mg/kg BID for a maximum of 24 months or until progression or until unacceptable toxicity.","id":"OG001","title":"Cohort B"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days post last dose (Up to 66 months)","title":"Number of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}